A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Adenoviridae/*enzymology ; Antineoplastic Agents/*therapeutic use ; Oncolytic Virotherapy/*methods ; Ovarian Neoplasms/*therapy ; Stomach Neoplasms/*therapy ; Thymidine Kinase/*chemistry; Adenoviridae/genetics ; Animals ; Apoptosis ; Cell Line, Tumor ; Cricetinae ; Female ; Flow Cytometry ; Genetic Vectors ; HEK293 Cells ; Hep G2 Cells ; Human Umbilical Vein Endothelial Cells ; Humans ; Male ; Mesocricetus ; Mice ; Mice, Inbred BALB C ; Neoplasm Transplantation ; Oncolytic Viruses/genetics ; Transgenes
    • Abstract:
      Adenovirus 5 vectors, known respectively as, the first generation, second generation and oncolytic adenovirus, have been studied extensively in preclinical and clinical trials. However, hitherto few systemic evaluations of the efficacy and toxicity of these adenoviral vectors that have reflected the vertical history of adenovirus based cancer gene therapy strategies have been undertaken. This study has chosen Adv-TK, the well-established adjuvant treatment in cancer, and compared its efficacy and safety with those of the two newly synthesized oncolytic adenovirus vectors encoding the HSV-TK gene, namely M7 and M8. The results obtained showed that systemic administration of 1×10(8) pfu M7 had an anti-tumour efficacy similar to that of 3×10(10) pfu Adv-TK whilst M8 performed even better. Furthermore, compared to Adv-TK, M7 and M8 reduced the incidence of metastases and substantially prolonged the survival time of the mice xenografted with human orthotopic gastric carcinomas with disseminated metastasis. Even more exciting, however, were the similar toxic and immune safety results obtained from the administration of high doses of M7 or M8 in comparison with Adv-TK in immunocompetent and permissive syrian hamster. The data here exhibit a comprehensive display of the efficacy and safety of the three mutants and provide evidence for the future preclinical use of the M7 and M8 viruses.
    • Comments:
      Erratum in: PLoS One. 2016;11(4):e0153540. (PMID: 27054322)
    • References:
      World J Surg. 2002 Jul;26(7):783-9. (PMID: 11948367)
      Toxicol Sci. 2008 Nov;106(1):242-50. (PMID: 18703561)
      Hum Gene Ther. 2002 Jan 1;13(1):15-63. (PMID: 11779412)
      Methods Mol Med. 2007;130:19-28. (PMID: 17401161)
      J Virol. 1996 Apr;70(4):2296-306. (PMID: 8642656)
      Carcinogenesis. 2009 Dec;30(12):2014-22. (PMID: 19843641)
      Acta Pharmacol Sin. 2009 May;30(5):617-27. (PMID: 19363518)
      Mol Ther. 2002 Aug;6(2):287-97. (PMID: 12349828)
      J Virol. 1992 Jun;66(6):3633-42. (PMID: 1316473)
      Cancer Res. 2000 Aug 1;60(15):3989-99. (PMID: 10945596)
      Cancer Gene Ther. 2006 Oct;13(10):930-9. (PMID: 16741520)
      Gene Ther. 2005 Mar;12(5):437-45. (PMID: 15647767)
      Biochem Biophys Res Commun. 2005 Sep 16;335(1):36-44. (PMID: 16051188)
      J Virol. 1999 Aug;73(8):6729-42. (PMID: 10400771)
      Hum Gene Ther. 1997 May 20;8(8):985-1001. (PMID: 9195221)
      Clin Cancer Res. 2007 Oct 1;13(19):5847-54. (PMID: 17908978)
      Cancer Res. 2003 Nov 1;63(21):7497-506. (PMID: 14612551)
      Gene Ther. 2001 Nov;8(21):1618-26. (PMID: 11895000)
      Cancer Res. 2001 Oct 15;61(20):7464-72. (PMID: 11606381)
      J Virol. 2003 Jul;77(14):7764-78. (PMID: 12829816)
      Virology. 1996 Jun 1;220(1):152-62. (PMID: 8659107)
      Nat Biotechnol. 2003 Nov;21(11):1328-35. (PMID: 14555956)
      Mol Ther. 2006 May;13(5):928-37. (PMID: 16459149)
      Curr Opin Immunol. 1999 Aug;11(4):380-6. (PMID: 10448144)
      Blood. 1997 Oct 1;90(7):2738-46. (PMID: 9326241)
      Am J Obstet Gynecol. 2007 Apr;196(4):389.e1-9; discussion 389.e9-10. (PMID: 17403430)
      Oncogene. 2000 Dec 27;19(56):6660-9. (PMID: 11426652)
      Mol Ther. 2008 Oct;16(10):1665-73. (PMID: 18665155)
      Clin Cancer Res. 2003 Feb;9(2):693-702. (PMID: 12576437)
      Cancer Gene Ther. 2009 Aug;16(8):644-54. (PMID: 19197324)
      Clin Cancer Res. 2005 Dec 1;11(23):8431-40. (PMID: 16322306)
      Gene Ther. 2001 Aug;8(15):1123-31. (PMID: 11509942)
      Methods Mol Biol. 2011;731:161-80. (PMID: 21516407)
      Cancer Res. 2002 Nov 1;62(21):6070-9. (PMID: 12414631)
      J Biol Chem. 2001 Feb 2;276(5):3270-8. (PMID: 11050095)
      Clin Cancer Res. 2000 Mar;6(3):798-806. (PMID: 10741699)
      Mol Cancer Ther. 2008 Jun;7(6):1624-32. (PMID: 18566233)
      Hum Gene Ther. 2001 Feb 10;12(3):219-26. (PMID: 11177559)
      Cancer Gene Ther. 2002 Mar;9(3):254-9. (PMID: 11896441)
      Mol Ther. 2001 Sep;4(3):182-91. (PMID: 11545608)
    • Accession Number:
      0 (Antineoplastic Agents)
      EC 2.7.1.21 (Thymidine Kinase)
    • Publication Date:
      Date Created: 20140412 Date Completed: 20150115 Latest Revision: 20211021
    • Publication Date:
      20221213
    • Accession Number:
      PMC3983249
    • Accession Number:
      10.1371/journal.pone.0094050
    • Accession Number:
      24722669